Lubrizol debuts paraben alternative
This article was originally published in The Rose Sheet
Executive SummaryWith the negative perception of paraben and formaldehyde preservatives in the marketplace, and shift to food-grade preservatives like sodium benzoate, Lubrizol Corporation releases Carbopol Aqua SF-2 polymer. Product is a "rheology modifier" that "delivers high clarity and superior suspension in the 4 to 6 pH range," says the Cleveland, Ohio-based company in a Sept. 13 release. Product will accommodate natural preservatives that require a pH level near 5 without sacrificing formulation clarity or flow properties, according to Lubrizol. "Now formulators can display colorful beads, sparkling pearls and exfoliating scrubs while also achieving claims of 'paraben-free,' 'formaldehyde-free,' 'preservative-free' and even 'skin neutral pH,'" firm explains. Potential uses for the polymer include clear bath gels, body scrubs with suspended microcapsules, facial scrubs with exfoliating beads, anti-acne facial cleansers with salicylic acid, pearlescent shampoos and soap-based cleansers
You may also be interested in...
US FDA commissioner Stephen Hahn and ORA associate commissioner for regulatory affairs Judith McMeekin said in a joint 24 February statement that the agency continues to aggressively monitor the market for any firms selling products with fraudulent COVID-19 prevention and treatment claims. The officials also explained that the FDA has the authority to ask for records from drug manufacturers in lieu of conducting facility inspections, but they didn’t say whether the agency would – or even could – ask the same of device makers. The FDA had announced on 14 February that it paused all inspections of Chinese manufacturing facilities in the near-term.
Knee implant manufacturer Conformis Inc. brings aboard new chief financial officer/treasurer and operations SVP; imaging and data management software company EyeKor promoted its president/CTO to CEO; and more.
Oncologic Drugs Advisory Committee will consider whether a statistically significant benefit on progression-free survival, but no survival advantage, is enough to secure a first-line lung cancer indication for ramucirumab.